We build strong relationships with our patients, payers and PBMs based on trust and quality of service.
Broad Access to Therapies
At Biologics, providing the best possible care for our patients means fostering relationships with biopharmaceutical and life sciences companies to ensure we provide industry-leading access to therapies. And our efforts to build these relationships show: today we carry over 165 cancer and rare disease drugs; we’re part of limited distribution networks for at least 92 of those, and we are the exclusive pharmacy for approximately 13.
How can we help?
Useful documents for your collaboration with Biologics.
Case Studies: How Biologics by McKesson Lowers Healthcare Costs
High Member Satisfaction
Our deepest relationships are with the patients we serve every day. We do everything in our power to ensure they not only have the best-possible clinical care, but also that they know they are cared about. 95% of our patients say our service is exceptional—but don’t take it from us. We’ll let them speak for themselves.
“During my treatment, I felt so supported by the Care Team who called me regularly. The calls made me feel so good! I wish I could spend more time with these wonderful people — they were so nice and helpful. And they really made me feel like they were there for me. They have my love and affection.”
— Marie, patient
“Every single person that I have dealt with at Biologics has been so wonderful and kind, and I am truly grateful for you all! Thank you!”
— Julie M., caregiver
Efficiency Paired with Innovation
With more than 500 unique contracts that help our specialty pharmacy ensure patients get the therapies and care they need, we know streamlined operations and a laser focus on cost management is critical. Our Biologics Market Access team has one mission — to prove to PBMs and payers that we bring real value to our relationship and your business.
Hidden costs driven by poor adherence and reduced productivity
Spent on medication-related hospitalizations
Hospitalizations are driven by medication non-adherence
Estimated revenue losses to pharma
$16,000 per patient
in losses from reduced productivity
We see drug cost through a different lens. Rather than over-focusing on drug pricing as a unit of cost, we consider the hidden — and very real — costs of non-adherence and avoidable side effects that can lead to things like expensive ER visits. Our patient care management programs are personalized for each patient, based on individual risk assessments, to provide exactly the right amount of care that enables patients to achieve the best-possible outcomes and mitigate these unnecessary costs.
We know it’s working — read this case study about our partnership with a PBM that proves what’s possible when we come together and focus on doing what’s right for patients.